摘要
目的研究银杏叶提取物对首发精神分裂症患者神经认知功能的改善程度。方法将268例符合CCMD-Ⅲ诊断标准的首发精神分裂症患者按住院号尾数的单双号分为研究组(132例)和对照组(136例)。研究组给予利培酮联合银杏叶提取物治疗,对照组予利培酮联合安慰剂治疗,共治疗12周。分别在入院时和治疗第4、8、12周后采用阳性和阴性症状量表(PANSS)和重复性神经心理状态测查量表(RBANS)评定患者神经认知功能的改善程度。结果从第4周末开始,两组患者PANSS总分及各分量表的分值均明显下降,与入院时比较差异均有统计学意义(均P<0.05)。治疗第12周末,两组患者PANSS总分、阳性分量表分、阴性分量表分、一般精神病理分的比较差异均有统计学意义(均P<0.05),且两组患者RBANS各因子分比较的差异有统计学意义(P<0.05),对照组在视觉广度、言语功能和注意方面的评分较入院时明显提高(P<0.05)。结论银杏叶提取物对改善神经认知功能障碍具有很好的治疗效果。
Objective To evaluate the clinical efficacy of ginkgo biloba （GB） extract on cognitive function for the first-episode schizophrenic patients. Methods A total of 268 patients with first-episode schizophrenia meeting the criteria of CCMD-3 were randomly assigned to receive risperidone plus GB （study group, n=132） or risperidone plus placebo （control group, n=136） for 12 weeks. The Positive and Negative Syndrome Scale （PANSS） and repeatable battery for the assessment of neuropsychological status （RBANS） were used to evaluate the cognitive function before and after treatment. Results The PANSS total score, the positive syndrome score, the negative syndrome score and the general psychopathological score were signifi-cantly decreased after treatment in GB group since the 4th week after treatment, compared with the control group （P〈0.05）. After 12 weeks of treatment, the PANSS total score, the positive syndrome score, the negative syndrome score and the general psy-chopathological score were significantly different between the two groups （P〈0.05）. The subscale scores of RBANS were signifi-cant different between the two groups （P〈0.05）; the visuospatial/ constructional, language and attention subscores were signifi-cantly increased in the control group （P〈0.05） compared to those before treatment. Conclusion The results suggest that therapy with adjunctive GB extract may improve deficit cognitive function in first-episode schizophrenic patients.
出处
《浙江医学》
CAS
2013年第8期678-680,共3页
Zhejiang Medical Journal
基金
温州市科技局基金项目(Y20100324)
